KCNS2 encodes Kv9.2, an electrically silent potassium channel regulatory subunit that modulates delayed rectifier voltage-gated potassium channel activity by forming functional heterotetrameric channels with KCNB1 (Kv2.1) and KCNB2 (Kv2.2) 1. KCNS2 alters channel kinetics, expression levels, and voltage-dependent inactivation properties, with each regulatory subunit exhibiting unique modulatory effects 1. In neurons, Kv2/KCNS2 heteromeric channels predominate in dorsal root ganglion neurons and can be distinguished pharmacologically from Kv2-only channels using selective inhibitors 1. Disease relevance includes essential tremor (ET): a heterozygous KCNS2 mutation (p.D379E) cosegregates with ET in families and causes neuronal hyperexcitability and altered sleep patterns in a Drosophila model 2. The mutation increased potassium channel inactivation and spontaneous neuronal firing rates, supporting pathogenicity 2. KCNS2 has also been identified as a circulating cell-free DNA methylation biomarker for pancreatic cancer early detection 3. Additionally, KCNS2 expression patterns correlate with cortical thickness changes in normative brain development and psychiatric disorders, with peak expression during pubertal neurodevelopment 4. These findings establish KCNS2 as crucial for neuronal excitability regulation and implicate its dysfunction in neurological and psychiatric disease pathogenesis.